research Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.
Search
for
Sort by
Research
240-270 / 1000+ resultsresearch Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
Topical JAK inhibitors may help children with alopecia areata regrow hair.
research Topical Janus kinase inhibitors: A review of applications in dermatology
Topical JAK inhibitors may help treat some skin conditions but need more research.
research The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research “Nomen Omen: The Myth of God Janus”
The name Janus is fitting for JAK inhibitors as they revolutionize dermatology treatments.
research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Alopecia areata
Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research Leptin and the skin: a new frontier
Leptin may improve skin regeneration and hair growth, and help reverse skin aging.
research Topical Ruxolitinib for the Treatment of Alopecia Universalis
Topical Ruxolitinib may safely treat severe hair loss.
research Tofacitinib for the treatment of lichen planopilaris: A case series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
research Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
research Treatment of pediatric alopecia areata: A systematic review
Topical corticosteroids are the best initial treatment for children's alopecia areata.
research Pathomechanisms of immune-mediated alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
research Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research The Diagnosis and Treatment of Hair and Scalp Diseases
Hair loss requires customized treatments based on its various causes and types.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.